Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 16/20 | 0.39 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.37 |
| ▸ | MAG | P20916 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402334 | 0.97 | CD22 (0.38) | CD22NANPMAG | |
| SCHEMBL14454530 | 0.93 | NANP (0.43) | CD22NANP | |
| SCHEMBL12341459 | 0.91 | NANP (0.39) | CD22NANPMAG | |
| SCHEMBL13402333 | 0.89 | CD22 (0.38) | CD22NANP | |
| SCHEMBL12341474 | 0.89 | CD22 (0.37) | CD22 | |
| SCHEMBL12341465 | 0.88 | CD22 (0.35) | CD22NANPMAG | |
| SCHEMBL13857469 | 0.88 | CD22 (0.36) | CD22NANPMAG | |
| SCHEMBL10260947 | 0.88 | CD22 (0.35) | CD22MAG | |
| SCHEMBL12341458 | 0.88 | NANP (0.38) | CD22NANP | |
| SCHEMBL12341443 | 0.87 | NANP (0.44) | CD22NANPMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029331-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2015-05-12 | — | — | US | disclosed |
| US-8911967-B2 | One pot desialylation and glycopegylation of therapeutic peptides | NOVO NORDISK A/S (DK) | 2014-12-16 | — | — | US | disclosed |
| US-8404809-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2013-03-26 | — | — | US | disclosed |
| US-8268967-B2 | Glycopegylated interferon α | NOVO NORDISK A/S (DK) | 2012-09-18 | — | — | US | disclosed |
| US-7956032-B2 | Glycopegylated granulocyte colony stimulating factor | NOVO NORDISK A/S (DK) | 2011-06-07 | — | — | US | disclosed |
| US-20100330645-A1 | ONE POT DESIALYLATION AND GLYCOPEGYLATION OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2010-12-30 | — | — | US | disclosed |
| US-7842661-B2 | Glycopegylated erythropoietin formulations | NOVO NORDISK A/S (DK) | 2010-11-30 | — | — | US | disclosed |
| US-20100210507-A9 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2010-08-19 | — | — | US | disclosed |
| US-20100113743-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20090292110-A1 | Enzymatic modification of glycopeptides | BIOGENERIX AG (DE) | 2009-11-26 | — | — | US | disclosed |
| US-20090203579-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | NOVO NORDISK A/S (DK) | 2009-08-13 | — | — | US | disclosed |
| US-20090081188-A1 | GLYCOPEGYLATED FACTOR IX | NEOSE TECHNOLOGIES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080305992-A1 | Glycopegylated erythropoietin | NEOSE TECHNOLOGIES, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080255026-A1 | Glycopegylated Factor Ix | GLYCOPEGYLATED FACTOR 1X | 2008-10-16 | — | — | US | disclosed |
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | 89BIO, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NEOSE TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | NEOSE TECHNOLOGIES, INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176790-A1 | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) | FGF2, FGF1, FGFR1 | CD22 392/4885NANP 163/4885MAG 711/4885 |
| US-20080146782-A1 | GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES | UGCG, B3GAT3, UGGT1 | CD22 367/4885NANP 306/4885MAG 119/4885 |
| US-20090081188-A1 | GLYCOPEGYLATED FACTOR IX | F9, F13A1, F13B | CD22 382/4885NANP 160/4885MAG 212/4885 |
| US-20100210507-A9 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | CD22 290/4885NANP 864/4885MAG 265/4885 |
| US-20090203579-A1 | Glycopegylated Granulocyte Colony Stimulating Factor | CSF3R, GMFG, GALNT1 | CD22 203/4885NANP 701/4885MAG 228/4885 |
| US-20080255026-A1 | Glycopegylated Factor Ix | F9, F13A1, F13B | CD22 390/4885NANP 156/4885MAG 194/4885 |
| US-20100113743-A1 | GLYCOPEGYLATED FACTOR VII AND FACTOR VIIA | F7, F13B, F13A1 | CD22 1638/4885NANP 431/4885MAG 576/4885 |
| US-20090292110-A1 | Enzymatic modification of glycopeptides | ENGASE, DNPEP, ENPEP | CD22 321/4885NANP 41/4885MAG 363/4885 |
| US-20070105755-A1 | One pot desialylation and glycopegylation of therapeutic peptides | UGGT1, PTMS, GALNT1 | CD22 210/4885NANP 832/4885MAG 802/4885 |
| US-20070014759-A1 | Glycopegylated granulocyte colony stimulating factor | CSF3R, GMFG, GALNT1 | CD22 203/4885NANP 701/4885MAG 228/4885 |
| US-20080305992-A1 | Glycopegylated erythropoietin | EPOR, UGGT1, GNE | CD22 290/4885NANP 864/4885MAG 265/4885 |
| US-20070154992-A1 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | GHITM, PTMS, GHRHR | CD22 2233/4885NANP 386/4885MAG 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.